Clinical Trial Update: Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update of huC242-DM4, a maytansinoid DM4–conjugated humanized monoclonal antibody, for solid tumors including pancreatic cancer; the study has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• huC242-DM4

Snippet

Sponsor: ImmunoGen, Inc. | Conditions: Non-colorectal Cancer, Pancreatic Cancer | Phase 1 | Status: COMPLETED